{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T12:40:27Z","timestamp":1787488827921,"version":"build-2736575974"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,9]]},"DOI":"10.7759\/cureus.91898","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T12:22:16Z","timestamp":1757420536000},"source":"Crossref","is-referenced-by-count":1,"title":["Effect of Esaxerenone in Patients With Persistent Atrial Fibrillation and Hypertension After Catheter Ablation"],"prefix":"10.7759","author":[{"given":"Manabu","family":"Kashiwagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Kuroi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuki","family":"Higashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Hata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Taruya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutsugu","family":"Shiono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yamano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Tanimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Kitabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac299","article-title":"Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease","volume":"43","author":"Pandey AK","year":"2022","unstructured":"Pandey AK, Bhatt DL, Cosentino F, et al.. Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Eur Heart J. 2022, 43:2931-45. 10.1093\/eurheartj\/ehac299","journal-title":"Eur Heart J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","article-title":"Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN Study)","volume":"75","author":"Ito S","year":"2020","unstructured":"Ito S, Itoh H, Rakugi H, Okuda Y, Yoshimura M, Yamakawa S. Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN Study). Hypertension. 2020, 75:51-8. 10.1161\/HYPERTENSIONAHA.119.13569","journal-title":"Hypertension"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-020-00606-w","article-title":"Efficacy and safety of esaxerenone in patients with hypertension and concomitant heart failure","volume":"44","author":"Naruke T","year":"2021","unstructured":"Naruke T, Maemura K, Oki T, et al.. Efficacy and safety of esaxerenone in patients with hypertension and concomitant heart failure. Hypertens Res. 2021, 44:601-3. 10.1038\/s41440-020-00606-w","journal-title":"Hypertens Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1253\/circrep.CR-21-0115","article-title":"Implication of mineralocorticoid receptor antagonist esaxerenone in patients with heart failure with preserved ejection fraction","volume":"3","author":"Imamura T","year":"2021","unstructured":"Imamura T, Oshima A, Narang N, Kinugawa K. Implication of mineralocorticoid receptor antagonist esaxerenone in patients with heart failure with preserved ejection fraction. Circ Rep. 2021, 3:660-5. 10.1253\/circrep.CR-21-0115","journal-title":"Circ Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0259485","article-title":"Safety and efficacy of esaxerenone in Japanese hypertensive patients with heart failure with reduced ejection fraction: a retrospective study","volume":"16","author":"Iwahana T","year":"2021","unstructured":"Iwahana T, Saito Y, Okada S, Kato H, Ono R, Kobayashi Y. Safety and efficacy of esaxerenone in Japanese hypertensive patients with heart failure with reduced ejection fraction: a retrospective study. PLoS One. 2021, 16:e0259485. 10.1371\/journal.pone.0259485","journal-title":"PLoS One"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02780-6","article-title":"Efficacy and safety of esaxerenone in hypertensive patients with left ventricular hypertrophy (ESES-LVH) study: a multicenter, open-label, prospective, interventional study","volume":"41","author":"Yamamoto E","year":"2024","unstructured":"Yamamoto E, Usuku H, Sueta D, et al.. Efficacy and safety of esaxerenone in hypertensive patients with left ventricular hypertrophy (ESES-LVH) study: a multicenter, open-label, prospective, interventional study. Adv Ther. 2024, 41:1284-303. 10.1007\/s12325-024-02780-6","journal-title":"Adv Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22042069","article-title":"Cardioprotective effects of a nonsteroidal mineralocorticoid receptor blocker, esaxerenone, in Dahl salt-sensitive hypertensive rats","volume":"22","author":"Rahman A","year":"2021","unstructured":"Rahman A, Sawano T, Sen A, et al.. Cardioprotective effects of a nonsteroidal mineralocorticoid receptor blocker, esaxerenone, in Dahl salt-sensitive hypertensive rats. Int J Mol Sci. 2021, 22:2069. 10.3390\/ijms22042069","journal-title":"Int J Mol Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2019422","article-title":"Early rhythm-control therapy in patients with atrial fibrillation","volume":"383","author":"Kirchhof P","year":"2020","unstructured":"Kirchhof P, Camm AJ, Goette A, et al.. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020, 383:1305-16. 10.1056\/NEJMoa2019422","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae580","article-title":"Radiofrequency catheter ablation of persistent atrial fibrillation by pulmonary vein isolation with or without left atrial posterior wall isolation: long-term outcomes of the CAPLA trial","volume":"46","author":"William J","year":"2025","unstructured":"William J, Chieng D, Curtin AG, et al.. Radiofrequency catheter ablation of persistent atrial fibrillation by pulmonary vein isolation with or without left atrial posterior wall isolation: long-term outcomes of the CAPLA trial. Eur Heart J. 2025, 46:132-43. 10.1093\/eurheartj\/ehae580","journal-title":"Eur Heart J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.11.070","article-title":"Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis","volume":"45","author":"Healey JS","year":"2005","unstructured":"Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, Connolly SJ. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005, 45:1832-9. 10.1016\/j.jacc.2004.11.070","journal-title":"J Am Coll Cardiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/clc.23659","article-title":"Radiofrequency catheter ablation combined with spironolactone in the treatment of atrial fibrillation: a single-center randomized controlled study","volume":"44","author":"Wang W","year":"2021","unstructured":"Wang W, Chen Q, Zhang F, et al.. Radiofrequency catheter ablation combined with spironolactone in the treatment of atrial fibrillation: a single-center randomized controlled study. Clin Cardiol. 2021, 44:1120-7. 10.1002\/clc.23659","journal-title":"Clin Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2012.12.020","article-title":"Effect of eplerenone on maintenance of sinus rhythm after catheter ablation in patients with long-standing persistent atrial fibrillation","volume":"111","author":"Ito Y","year":"2013","unstructured":"Ito Y, Yamasaki H, Naruse Y, et al.. Effect of eplerenone on maintenance of sinus rhythm after catheter ablation in patients with long-standing persistent atrial fibrillation. Am J Cardiol. 2013, 111:1012-8. 10.1016\/j.amjcard.2012.12.020","journal-title":"Am J Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2023.04.038","article-title":"A systematic review and meta-analysis on effectiveness of mineralocorticoid receptor antagonists in reducing the risk of atrial fibrillation","volume":"199","author":"Fatima K","year":"2023","unstructured":"Fatima K, Asad D, Shaikh N, et al.. A systematic review and meta-analysis on effectiveness of mineralocorticoid receptor antagonists in reducing the risk of atrial fibrillation. Am J Cardiol. 2023, 199:85-91. 10.1016\/j.amjcard.2023.04.038","journal-title":"Am J Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.04.079","article-title":"Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes","volume":"78","author":"Filippatos G","year":"2021","unstructured":"Filippatos G, Bakris GL, Pitt B, et al.. Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes. J Am Coll Cardiol. 2021, 78:142-52. 10.1016\/j.jacc.2021.04.079","journal-title":"J Am Coll Cardiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2005.10.005","article-title":"Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology","volume":"18","author":"Lang RM","year":"2005","unstructured":"Lang RM, Bierig M, Devereux RB, et al.. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005, 18:1440-63. 10.1016\/j.echo.2005.10.005","journal-title":"J Am Soc Echocardiogr"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.019406","article-title":"Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial","volume":"133","author":"Di Biase L","year":"2016","unstructured":"Di Biase L, Mohanty P, Mohanty S, et al.. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. Circulation. 2016, 133:1637-44. 10.1161\/CIRCULATIONAHA.115.019406","journal-title":"Circulation"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon SD","year":"2024","unstructured":"Solomon SD, McMurray JJ, Vaduganathan M, et al.. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024, 391:1475-85. 10.1056\/NEJMoa2407107","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.007252","article-title":"Plasma B-type natriuretic peptide levels and recurrent arrhythmia after successful ablation of lone atrial fibrillation","volume":"123","author":"Hussein AA","year":"2011","unstructured":"Hussein AA, Saliba WI, Martin DO, et al.. Plasma B-type natriuretic peptide levels and recurrent arrhythmia after successful ablation of lone atrial fibrillation. Circulation. 2011, 123:2077-82. 10.1161\/CIRCULATIONAHA.110.007252","journal-title":"Circulation"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.33963\/KP.a2022.0191","article-title":"Association of left atrial enlargement and increased left ventricular wall thickness with arrhythmia recurrence after cryoballoon ablation for atrial fibrillation","volume":"80","author":"Warmi\u0144ski G","year":"2022","unstructured":"Warmi\u0144ski G, Urbanek P, Orczykowski M, et al.. Association of left atrial enlargement and increased left ventricular wall thickness with arrhythmia recurrence after cryoballoon ablation for atrial fibrillation. Kardiol Pol. 2022, 80:1104-11. 10.33963\/KP.a2022.0191","journal-title":"Kardiol Pol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/408262-effect-of-esaxerenone-in-patients-with-persistent-atrial-fibrillation-and-hypertension-after-catheter-ablation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T12:22:17Z","timestamp":1757420537000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/408262-effect-of-esaxerenone-in-patients-with-persistent-atrial-fibrillation-and-hypertension-after-catheter-ablation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.91898","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,9]]}}}